{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-054942","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.981070+00:00","generated_at":"2026-05-14T23:49:35.562975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M","bullets":["Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).","Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.","Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.","FY2026 revenue guidance raised to $192M-$196M versus prior outlook.","Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-054942","json":"https://secwatch.observer/filing/0001104659-26-054942.json","markdown":"https://secwatch.observer/filing/0001104659-26-054942.md","text":"https://secwatch.observer/filing/0001104659-26-054942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/tm2613494d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:49:35.562975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"151128f52958b9e91a1b709e479318f6f4f1b685","claim":"Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.","evidence_excerpt":"99.1) --- EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results ● First quarter revenue grew 16% year-over-year to $47.8 million ● Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs ● Life Sciences Services","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter (Q1) of 2026"},{"label":"Revenue","value":"$47.8 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}